

oncology pipeline

IMMUNO- ONCOLOGY


Assets

View More

Avelumab

anti-PD-L1 mAb


Development Phase **II** **III**



Bintrafusp alfa

TGF- β "trap"/anti-PD-L1


Development Phase **I** **II**



M6223

anti-TIGIT mAb

Development Phase **I**



DNA DAMAGE RESPONSE (DDR)

Assets

View More

Peposertib (M3814)

DNA-PK inhibitor

Development Phase **I**



Berzosertib (M6620)

ATR inhibitor

Development Phase **I** **II**



M1774

ATR inhibitor

Development Phase **I**



M4076

ATM inhibitor

Development Phase **I**



ONCOGENIC PATHWAYS

Assets

View More

Tepotinib

MET kinase inhibitor

Development Phase **II**



Xevinapant

Inhibitor of apoptosis proteins (IAP)

Development Phase **III**



M1231

Anti-EGFR and MUC1 ADC

Development Phase **I**




Updated: August 2021

The Healthcare business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the United States and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

**EMD
SERONO**

US-MULOP-00032 | August 2021




1L, first-line treatment; 2L, second-line treatment.

¹Avelumab is being co-developed and co-marketed by Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc.

²Bintrafusp alfa is being developed in a strategic global alliance between Merck KGaA, Darmstadt, Germany, and GSK.

The Healthcare business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the United States and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.



ONCOGENIC PATHWAYS

tepotinib
MET kinase inhibitor

xevinapant
Inhibitor of apoptosis proteins (IAP)

M1231
Anti-EGFR and MUC1 ADC

TREATMENT

TUMOR SETTING

DEVELOPMENT PHASE

I

II

III

Combination with osimertinib

EGFR TKI-relapsed *MET*-amplified NSCLC

Combination with cetuximab

Left-sided *RAS/BRAF* wild-type mCRC with *MET* amplification

Combination with chemoradiotherapy

Locally advanced SCCHN

Monotherapy

Solid tumors